CURE Pharmaceutical’s Subsidiary Sera Labs Launches National Television, Radio & Digital Advertising Campaign for Nutri-Strips Sleep A.S.A.P.

March 3, 2021 13:15 UTC


Sleep A.S.A.P. provides proof of concept and monetization for CURE’s patented oral thin-film technology


LOS ANGELES & OXNARD, Calif.--(BUSINESS WIRE)-- CURE Pharmaceutical. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space today announced that its subsidiary Sera Labs has launched a robust national advertising campaign for its Nutri-Strips thin-film product Sleep A.S.A.P.™ which offers a solution to America’s sleep problem. The global market for sleep aids is anticipated to grow from $81.2 billion in 2020 to $112.7 billion by 2025 with a CAGR of 6.8 percent.

The national campaign will debut in more than 15 major markets and target the 70% of adults in America who, according to the CDC, report they obtain insufficient sleep at least one night per week. The campaign will coincide with National Sleep Awareness Month and highlight the ease of use and benefits of Nutri-Strips’ RAD₃ (Rapid Activation Delivery) oral thin-film strip technology. Nutri-Strips Sleep A.S.A.P.™ oral thin-film strip does not require water, activates instantly on the tongue, is a fast-acting, non-habit forming solution to traditional pill form sleep aids.

Sleep A.S.A.P.™’s proprietary formulation for sleep was developed by CURE’s industry-leading scientists who blended five of the most powerful sleep ingredients including Melatonin, Gamma-aminobutyric Acid (GABA), L-Theanine, Vitamin B6, and Beta-Caryophyllene (BCP) into one dose to help you get to sleep and stay asleep.

“Nutri-Strips serve as a strong proof of concept for CURE’s patented oral thin-film technology and this campaign highlights the fact that we can successfully commercialize and monetize this technology through our subsidiary Sera Labs,” said Rob Davidson, CEO of CURE. “We foresee this type of advertising exposure as an opportunity to further introduce the world to the thin-film technology, which is a staple of both CURE's pharmaceutical and wellness verticals, while generating consumer sales."

“We are very excited to launch this innovative technology to the consumer for the first time offering evidence-based products with science-backed ingredients,” said Nancy Duitch, Sera Labs CEO and CURE Pharmaceutical Chief Strategic Officer. “In additional to our extensive marketing campaign, we have created educational resources for consumers and retailers to easily understand the technology behind Nutri-Strips as well as demonstrable packaging in order to create a brand that stands out in the nutraceutical space. We are more than optimistic about this product's future along with our other Nutri-Strips products which we are launching simultaneously.”

Visit to learn more about Nutri-Strips, follow us @nutristrips or

About SeraLabs

Sera Labs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical™, SeraLabs™, and Gordon’s Herbals™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness, and pet care, Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: and follow us on Instagram at @theseralabs, Twitter, or on Facebook or contact:

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.

As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Forward Looking Statement

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


Licensing Contact:
Jonathan Berlent
Chief Business Officer
CURE Pharmaceutical

Investment Contact:
Gary Zwetchkenbaum
Plum Tree Consulting LLC

Media Contacts:

Monica M. Jaramillo
LABEL the Agency

Investor & Corporate Relations
Kathryn Brown
CMW Media


Source: CURE Pharmaceutical

Back to news